Revista de Gravidez e Saúde Infantil

Abstrato

Response to Hydrolysed Collagen Protein Supplementation in a Cohort of Pregnant and Postpartum Women

Leon Baginski, Marc Winter, Thomas S Bailey, Scott Capobianco, Marsha Granese, Freddie Granger MA, Kurt Miller, Kerry Price, Sara Ramirez, Craig Salcido, Frank Turner* and Mary O’Toole

There is overwhelming evidence that links maternal nutrition during pregnancy with fetal outcomes. This study evaluated the safety and efficacy of Protiva treatment responses in pre and postpartum female subjects between the ages of 19 years and 43 years who entered into this open label study. The protocol was designed to take a twice daily collagen protein supplementation drink during the third trimester and for 10 weeks postpartum. The outcomes were measured against a control group of patients who did not take the protein supplementation. The differences between mean score for the physical health domain of WHOQOL-BREF scale in the Protiva group and the control group were different and met statistical significance (p=0.0003). The study found that 100% of control patients and 95% of Protiva patients had initial serum protein levels below the normal median range and 27% of control patients and 33% of Protiva patients were below normal range. With collagen protein supplementation we were able to demonstrate improved quality of life and wound healing rates and 100% improvement in the protein levels for Protiva patients and a 72% improvement over control patients. Protiva Pregnancy and Protiva New Mom was determined to be safe and well tolerated when taken during pregnancy and post-partum during the study.